American Pharmacy News Reports Stories

Fluarix Quadrivalent was approved in 2012 in the United States to prevent influenza.

GSK has submitted a supplemental Biologics License Application for Fluarix Quadrivalent (influenza vaccine) to the U.S. Food and Drug Administration. Read More »

Bavencio gains FDA approval for intravenous use

Bavencio was approved by the FDA for intravenous use.

Pfizer Inc. and EMD Serono, Merck KHaA’s biopharmaceutical arm in the United States and Canada, recently announced that Bavencio was approved by the Food and Drug Administration for intravenous use. Read More »

Portola Pharmaceuticals present new data from betrixaban and AndexXa studies

Portola Pharmaceuticals presented data from its pivotal Phase 3 APEX study for the investigational drug betrixaban.

Portola Pharmaceuticals Inc. presented data from its pivotal Phase 3 APEX study for the investigational drug betrixaban at a poster session at the American College of Cardiology’s 66th Annual Scientific Session & Expo. Read More »

Sanofi and Regeneron present data on Praluent at ACC 17 event

Sanofi is a global health care company that focuses on therapeutic solutions.

Sanofi and Regeneron Pharmaceuticals Inc. recently presented Phase 3 clinical trial data and multiple additional analyses from the Praluent (alirocumab) Injection's Odyssey clinical trial program at the American College of Cardiology Scientific Sessions in Washington, D.C. Read More »

Protagonist Therapeutics, Janssen Biotech to share PTG-200 rights

Janssen and Protagonist will be co-funding the development of the antagonist through Phase 2.

Protagonist Therapeutics Inc., announced May 30 that they have formed a worldwide license and collaboration with Janssen Biotech Inc. Read More »

Biohaven responds to need by developing medication for SCA

Spinocerebellar ataxia affects 22,000 Americans.

Biohaven Pharmaceutical Holding Company Ltd. has finished its enrollment in the clinical study for trigriluzole for individuals with spinocerebellar ataxia, a rare neurodegenerative disorder. Read More »

Diplomat Pharmacy offers new rheumatoid arthritis treatment

Approximately 1.5 million individuals in the U.S. suffer from rheumatoid arthritis.

Diplomat Pharmacy Inc. is now filling prescriptions for KEVZARA (sarilumab), an FDA-approved medication for the treatment of moderate-to-severe rheumatoid arthritis (RA) in patients who are intolerant to or not receiving enough of a response from other disease modifying antirheumatic drugs. Read More »

Innovus Pharmaceuticals signs license and distribution agreement with Luminarie

Female Sexual Dysfunction is estimated to affect 43 percent of women in the U.S. between 18 and 59.

Innovus Pharmaceuticals Inc. is signing an exclusive license and distribution agreement for commercialization of Zestra and Zestra Glide with Luminarie Pty Ltd. throughout Australia, New Zealand and the Philippines. Read More »

Sierra Oncology receives patent for Chk1 inhibitor

The patent that Sierra has been granted will provide the company with coverage until 2033.

Sierra Oncology has been granted a selection patent for its Chk1 inhibitor, SRA737 by the U.S. Patent and Trademark Office. Read More »

Technavio projects explosive growth for pharmaceutical packaging market

Tabitha Fleming | Jun 4, 2017

The market for parenteral containers -- containers that include vials, injections, ampoules and pre-filled syringes -- is expected to grow.

According to the Technavio’s latest market study, the North American pharmaceutical packaging market is expected to grow through 2021. Read More »

PCMA applauds FDA attempts to stop prescription drug price-fixing

Generic medications provide a lower cost alternative to consumers.

The Pharmaceutical Care Management Association (PCMA) released a statement in support of the Food and Drug Commissioner’s call to publish a list of off-patent drugs that may be vulnerable to price-fixing. Read More »

BioPharma Services passes trio of FDA inspections

The company has clinical facilities in Canada and the United States that can accommodate 250 patients.

BioPharma Services Inc. recently passed three Food and Drug Administration inspections without a single Form 483 being issued. Read More »

Direct Relief teams with Pfizer in response to opioid epidemic

LocalLabs News Service | Jun 2, 2017

Direct Relief has already delivered 45,000 doses of life-saving Naloxone to communities hit hardest by the opiod epidemic.

Direct Relief is working with Pfizer to provide up to a million doses of life-saving Naloxone to community health centers, free clinics, public health departments and other non-profits nationwide in response to the opioid epidemic. Read More »

ScriptSave partners with Physicians Mutual

ScriptSave focuses on solutions for health care and prescription coverage gaps.

ScriptSave recently announced that it has partnered with Physicians Mutual to provide discounts on prescription medication to Physicians Mutual customers through its ScriptSave WellRx program. Read More »

Merck's HIV drug receives preliminary European approval

Patients who weigh at least 88 pounds should take two of the tablets once a day.

Merck has received approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for ISENTRESS, a 600 mg. tablet coated in film and paired with other anti-retroviral prescriptions for those who have been diagnosed HIV-1. Read More »

FDA to review Aptiom for children who experience seizures

The FDA decision could come up with a decision as soon as Sept. 13 under the Prescription Drug User Fee Act.

The FDA says it is willing to look into and evaluate a drug that could help treat children who suffer from seizures. Read More »

Hematogenix included as Merck & Co. lab for FDA-approved PD-L1 companion